Board approves merger with Ipca Laboratories

Listed Co AcquisitionDemerger Ratio AnnouncedStrategic Transactions View source PDF

KREBSBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-8.2%1-day move

₹66.24

prior close

₹65.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-5.8—-3.3—-8.2-9.4-11.4-12.1-11.7-18.5-18.5———

Up moveDown movePending

AI summary

Krebs Biochemicals board approved a merger with Ipca Laboratories under a scheme of amalgamation. Shareholders will get 7 Ipca shares for every 200 Krebs shares. No cash consideration. Appointed date April 1, 2026. Krebs has fermentation API capability Ipca needs but lacks. Krebs has been loss-making. Ipca FY26 total income Rs.7,431 crore versus Krebs Rs.26 crore. Subject to NCLT and SEBI approvals.

Likely market impact

Krebs holders get Ipca shares in swap. Likely positive given Ipca's larger size and financial strength. Awaiting NCLT and SEBI approvals.